# Ceralasertib

Source: https://onco.cc/drugs/ceralasertib/  
OnCo record `ceralasertib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ceralasertib is an experimental small-molecule drug from AstraZeneca in phase 3 trials for non-small-cell lung cancer, melanoma and triple-negative breast cancer, aimed at ATR.

## Summary

Ceralasertib (AZD6738) is a small-molecule drug developed by AstraZeneca. Its target is ATR (the sponsor names ATR (Ataxia Telangiectasia and Rad3-related) kinase). The sponsor states: Ceralasertib is an oral small-molecule ATR kinase inhibitor, tested here in combination with the PD-L1 inhibitor durvalumab; the CT.gov record's exclusion criterion barring prior ATR inhibitor use is consistent with this. ClinicalTrials.gov describes the intervention as: Participants will receive oral tablet of ceralasertib as stated in arm description. It is the investigational product in 5 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05450692 (A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy), in non-small-cell lung cancer, melanoma and triple-negative breast cancer. The largest, NCT05450692, plans to enrol 594 participants (actual) with primary completion was scheduled for 2025-10-06 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: AZD6738
- Modality: small molecule
- Mechanism: Ceralasertib is an oral small-molecule ATR kinase inhibitor, tested here in combination with the PD-L1 inhibitor durvalumab; the CT.gov record's exclusion criterion barring prior ATR inhibitor use is consistent with this.

## Sources

- ClinicalTrials.gov: trials of Ceralasertib: https://clinicaltrials.gov/search?intr=AZD6738

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [ATR](https://onco.cc/targets/atr/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy](https://onco.cc/trials/nct05450692/), [A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition](https://onco.cc/trials/nct05061134/), [A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy](https://onco.cc/trials/nct05941897/), [Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy](https://onco.cc/trials/nct03334617/), [PHOENIX DDR/Anti-PD-L1](https://onco.cc/trials/phoenix/), [Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel](https://onco.cc/trials/nct05582538/), [Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06732401/), [To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.](https://onco.cc/trials/nct03330847/)

---
JSON: https://onco.cc/api/v1/entities/ceralasertib.json